SCHEMBL5135778

SCHEMBL5135778

O=C(CN1CCc2ccccc2C1c1cccc(Cl)c1)N(Cc1ccccc1F)C1Cc2ccccc2C1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.52
HDAC8 Q9BY41 6/20 0.43
HDAC1 Q13547 5/20 0.42
HDAC3 O15379 4/20 0.38
NCOR2 Q9Y618 4/20 0.38
HDAC2 Q92769 3/20 0.38
ALDH1A1 P00352 2/20 0.37
PRCP P42785 2/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
OPRM1 P35372 1/20 0.36
MAPT P10636 1/20 0.36
HSD17B10 Q99714 1/20 0.36
HTR2A P28223 3/20 0.35
HTR2C P28335 3/20 0.35
HTR2B P41595 3/20 0.35
HRH3 Q9Y5N1 3/20 0.35
KDM4E B2RXH2 1/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5136532 0.91 C5AR1 (0.52) C5AR1HDAC8HDAC1HDAC3NCOR2
SCHEMBL5136309 0.90 C5AR1 (0.55) C5AR1HDAC8HDAC1HDAC3NCOR2
SCHEMBL5136248 0.90 C5AR1 (0.54) C5AR1HDAC8HDAC1HDAC3NCOR2
SCHEMBL5135530 0.89 HDAC8 (0.55) C5AR1HDAC8HDAC1HDAC3NCOR2
SCHEMBL5135133 0.87 C5AR1 (0.54) C5AR1HDAC8HDAC1HDAC3NCOR2
SCHEMBL5135156 0.87 C5AR1 (0.53) C5AR1HDAC8HDAC1HDAC3NCOR2
SCHEMBL5134974 0.87 C5AR1 (0.53) C5AR1HDAC8HDAC1HDAC3NCOR2
SCHEMBL5136178 0.87 C5AR1 (0.51) C5AR1HDAC8ALDH1A1MEN1KMT2A
SCHEMBL5134730 0.87 C5AR1 (0.57) C5AR1HDAC8HDAC1HDAC3NCOR2
SCHEMBL5134943 0.87 C5AR1 (0.57) C5AR1HDAC8HDAC1HDAC3NCOR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed